Skip to main content

Table 7 Scenarios summary

From: Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis

Scenario Description
Scenario 1: LEAD study baseline cohort Base case analysis repeated using baseline characteristics reported in the LEAD study
Scenario 2: split between SHE1:SHE2 as 1:1 Adjusted the proportion of hypoglycemia requiring (SHE2) versus not-requiring medical (SHE1) assistance to 1:1. In base case, the percentage of SHE2 is set as 11.8% of total hypoglycemia rate
Scenario 3: efficacy adjusted Assumed that the rates of severe hypoglycaemia were at the upper bound of the 95% CI of glargine U100 treatment and the lower bound of 95% CI of NPH treatment
Scenario 4: PROcam risk equations Repeated analysis using PROcam risk equations to predict outcomes
Scenario 5: UKPDS 82 risk equations Repeated analysis using UKPDS 82 risk equations to predict outcomes
  1. SHE1 severe hypoglycemia not requiring medical assistance, SHE2 severe hypoglycemia requiring medical assistance